Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen

Haematologica. 2007 Jan;92(1):139-40. doi: 10.3324/haematol.10564.

Abstract

We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bronchoalveolar Lavage Fluid
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, B-Cell / complications*
  • Lymphoma, B-Cell / drug therapy
  • Microscopy, Fluorescence
  • Middle Aged
  • Pneumocystis / metabolism*
  • Pneumonia, Pneumocystis / complications*
  • Pneumonia, Pneumocystis / drug therapy
  • Polymerase Chain Reaction
  • Prednisone / administration & dosage
  • Rituximab
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol